Delving into the Latest Updates on Sichuan Anaerobic Biotechnology Co., Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Infectious Diseases

Other Diseases

Biological products

Probiotics

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Biological products	2
Probiotics	1

[Translation] A prospective, multicenter, randomized, double-blind, placebo-controlled phase IIb clinical trial to evaluate the safety and efficacy of sequential vaginal administration of metronidazole followed by KAL-001, a quadruple-lactobacillus capsule, in the treatment of bacterial vaginosis (BV)

1.评价甲硝唑序贯阴道用四联乳杆菌活菌胶囊KAL-001治疗BV患者的有效性。 2.评估甲硝唑序贯阴道用四联乳杆菌活菌胶囊KAL-001预防BV三个月复发的有效性； 3.评估甲硝唑序贯阴道用四联乳杆菌活菌胶囊KAL-001治疗BV患者的安全性。 4.探索用药前后阴道分泌物中微生物群落特征变化；

[Translation]

1. Evaluate the effectiveness of metronidazole followed by vaginal tetra-lactobacillus capsule KAL-001 in the treatment of BV patients. 2. Evaluate the effectiveness of metronidazole followed by vaginal tetra-lactobacillus capsule KAL-001 in preventing BV recurrence for three months; 3. Evaluate the safety of metronidazole followed by vaginal tetra-lactobacillus capsule KAL-001 in the treatment of BV patients. 4. Explore the changes in the characteristics of the microbial community in vaginal secretions before and after medication;

Start Date23 May 2024

Sponsor / Collaborator

Sichuan Anaerobic Biotechnology Co., Ltd.

CTR20230471 / Active, not recruitingPhase 2

一项多中心、随机、双盲、安慰剂对照评价阴道用四联乳杆菌活菌胶囊治疗绝经后萎缩性阴道炎有效性和安全性的Ⅱ期临床研究

[Translation] A multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of vaginal Lactobacillus quadruple live capsules in the treatment of postmenopausal atrophic vaginitis

1.评价阴道用四联乳杆菌活菌胶囊改善绝经后萎缩性阴道炎（PAV）受试者阴道微生态状态的有效性和安全性。 2.评价阴道用四联乳杆菌活菌胶囊改善PAV受试者阴道症状和阴道体征的有效性，以及阴道用四联乳杆菌活菌胶囊在PAV受试者阴道菌群定植； 3.探索阴道用四联乳杆菌活菌胶囊改善PAV受试者女性性功能和阴道衰老相关生活质量（QoL）方面的有效性。

[Translation]

1. To evaluate the effectiveness and safety of vaginal Lactobacillus tetra-lactobacillus capsules in improving the vaginal microecological status of subjects with postmenopausal atrophic vaginitis (PAV). 2. To evaluate the effectiveness of vaginal Lactobacillus tetra-lactobacillus capsules in improving vaginal symptoms and signs in PAV subjects, as well as vaginal colonization of vaginal flora in PAV subjects; 3. To explore the effectiveness of vaginal Lactobacillus tetra-lactobacillus capsules in improving female sexual function and vaginal aging-related quality of life (QoL) in PAV subjects.

Start Date17 May 2023

Sponsor / Collaborator

Sichuan Anaerobic Biotechnology Co., Ltd.

CTR20220546 / Active, not recruitingPhase 2

评价阴道用四联乳杆菌活菌胶囊治疗细菌性阴道病（BV）的安全性及有效性的前瞻性、多中心、随机、双盲、阳性对照的Ⅱ期临床试验

[Translation] A prospective, multicenter, randomized, double-blind, positive-controlled phase II clinical trial to evaluate the safety and efficacy of vaginal tetravalent lactobacillus capsules in the treatment of bacterial vaginosis (BV)

1、评价不同剂量的阴道用四联乳杆菌活菌胶囊治疗 BV 患者的有效性和安全性。 2、探索用药前后患者阴道分泌物中微生物群落特征变化，观察治疗结束后 22±3 天患者 BV 的治愈率。

[Translation]

1. Evaluate the efficacy and safety of different doses of vaginal tetra-lactobacillus capsules in the treatment of BV patients. 2. Explore the changes in the characteristics of the microbial community in the vaginal secretions of patients before and after medication, and observe the cure rate of BV in patients 22±3 days after the end of treatment.

Start Date16 Jun 2022

Sponsor / Collaborator

Sichuan Anaerobic Biotechnology Co., Ltd.

100 Clinical Results associated with Sichuan Anaerobic Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Sichuan Anaerobic Biotechnology Co., Ltd.

Login to view more data

1

Literatures (Medical) associated with Sichuan Anaerobic Biotechnology Co., Ltd.

Agronomy

Culturomics and Amplicon-Based Metagenomic Insights into the Bacteria of Soils with High Yield of Oryza sativa L. subsp. Japonica

Author: Ruan, Wenzhong ; Cao, Qingmei ; Guo, Yapeng ; Ruan, Zhiyong ; Li, Yan ; Zhuang, Yan ; Zhang, Li

The bacterial community in the paddy field agroecosystem has a pivotal role in the growth adaptability strategy of rice. Here, we studied the bacterial community structure composition of rhizosphere and non-rhizosphere soil samples from super rice in high-yield (920.99 kg/mu) and low-yield (785.30 kg/mu) fields of Japonica Chu 54 using both culturomics and amplicon-based metagenomics approaches. Using amplicon sequencing, a total of 54 phyla and 1167 genera of high-yield field bacteria were detected, while the low-yield field bacteria were distributed in 49 phyla and 865 genera. In addition, compared with low-yielding fields, there were significant differences in the composition and abundance of the same members in high-yielding fields. The node microorganisms in high-yield and low-yield fields were Anaeromyxobacterium and HSB_OF53-F07, respectively. Culturomics analysis unveiled a diverse array of bacterial taxa, encompassing four phyla, 113 genera, and 331 species, including 33 new undescribed lineages. The culturomics and high-throughput sequencing results indicate a widely adapted and highly abundant group of Exiguobacterium, which has broad prospects for application due to its extensive survival characteristics and plant growth-promoting functions. In summary, we analyze the bacterial community structure composition of rhizosphere and non-rhizosphere soil samples from super rice in high-yield and low-yield fields of Japonica Chu 54 using culturomics and amplicon sequencing techniques to better develop positive promotion strategies that adapt to its unique ecological environment.

100 Deals associated with Sichuan Anaerobic Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Sichuan Anaerobic Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

1

IND Approval

Phase 2 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Viable Lactobacillus Quadruple (Sichuan Yanyang Biotechnology)	Bacterial Vaginosis More	Phase 2
KAL-002	Radiation proctitis More	IND Approval
KAL-003	-	IND Application